A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
- Conditions
- Melanoma
- Interventions
- Registration Number
- NCT05608291
- Lead Sponsor
- Regeneron Pharmaceuticals
- Brief Summary
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab.
The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting.
The study is looking at several other research questions, including:
* What side effects may happen from receiving the study drugs.
* How much study drug is in the blood at different times.
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections.
* How administering the study drugs might improve quality of life.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1564
- All patients must be either stage IIB, IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that is completely surgically resected in order to be eligible as defined by the protocol
- Complete surgical resection must be performed within 12 weeks prior to randomization, and enrollment may occur only after satisfactory wound healing from the surgery
- All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization, as described in the protocol
Key
- Uveal melanoma
- Any evidence of residual disease after surgery by imaging, pathology, or cytology.
- Ongoing or recent (within 2 years) evidence of clinically significant autoimmune disease that required treatment
- Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection, as described in the protocol
- Another malignancy that is currently progressing or that required active treatment in the past 5 years, as described in the protocol
- Participants with a history of myocarditis
- Adolescent patients (≥12 to <18 years old) with body weight <40 kg
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Fianlimab HD + Cemiplimab Fianlimab Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab Fianlimab HD + Cemiplimab Cemiplimab Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab Fianlimab LD + Cemiplimab Fianlimab Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab Fianlimab LD + Cemiplimab Cemiplimab Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab Pembrolizumab Pembrolizumab Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo Pembrolizumab Placebo Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo
- Primary Outcome Measures
Name Time Method Relapse free survival (RSF) Up to 5 Years Time from randomization to the first documented recurrence of disease at any site (excluding new primary melanomas) or death from any cause, whichever occurs first.
- Secondary Outcome Measures
Name Time Method Distant metastasis-free survival (DMFS) Up to 5 Years Time between the date of randomization and the date of the first distant metastasis.
Occurrence of immune-mediated EAEs (im-EAEs) Up to 5 Years imAEs are a unique set of toxicities thought to be caused by unrestrained cellular immune responses.
Overall survival (OS) Up to 5 Years Time from randomization to the date of death.
Occurrence of treatment-emergent adverse events (TEAEs) Up to 5 Years A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Occurrence of serious adverse events (SAEs) Up to 5 Years An SAE is any untoward medical occurrence that at any dose:
* Results in death - includes all deaths, even those that appear to be completely unrelated to study drug (eg, a car accident in which a patient is a passenger).
* Is life-threatening
* Requires in-patient hospitalization or prolongation of existing hospitalization.
* Results in persistent or significant disability/incapacity
* Is a congenital anomaly/birth defect.
* Is an important medical eventOccurrence of adverse events of special interest (AESIs) Up to 5 Years An AESI (serious or non-serious) is one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the sponsor can be appropriate. Such an event might warrant further investigation in order to characterize and understand it
Occurrence of laboratory abnormalities Up to 5 Years As assessed by the NCI-CTCAE grading system (≥ Grade 3 or higher)
Concentrations of fianlimab in serum over time Up to 5 Years The concentrations of fianlimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.
Patient report outcomes (PRO) for adults as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30) Up to 5 Year The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.
The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. More points are considered to have a better outcome.PRO for adults as measured by the European Quality of Life Dimension 5 (EQ-5D-5L) Up to 5 Years The EQ-5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
PRO for adults as determined by the Patient Global Impressions Scale (PGIS) Up to 5 Years The PGIS is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time by using a 4-point Likert scale that ranges from (1) = "none (no symptoms)" to (4) = "severe".
Time to physical functioning deterioration per EORTC QLQ-C30 Up to 5 Years Occurrence of TEAEs resulting in death Up to 5 Years A TEAE resulting in death is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Occurrence of dose-limiting toxicity (DLT) Up to 5 Years A DLT is defined as a study-drug related TEAE, including imAEs, that could preclude enrolling additional adolescent patients at the selected dose. Dose-limiting toxicity will be evaluated in adolescents only.
Occurrence of interruption or discontinuation of study drug(s) due to TEAE Up to 5 Years A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Concentrations of cemiplimab in serum over time Up to 5 Years The concentrations of cemiplimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.
Concentration of finalimab anti-drug antibodies (ADA) and neutralizing antibodies Up to 5 Years Immunogenicity will be characterized per drug molecule by ADA and NAb status.
Concentration of cemiplimab anti-drug antibodies (ADA) and neutralizing antibodies Up to 5 Years Immunogenicity will be characterized per drug molecule by ADA and NAb status.
PRO for adults as determined by the Patient Global Impressions of Change Scale (PGIC) Up to 5 Years The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 5-point Likert scale anchored by (1) "much better" to (5) "much worse", with (4) = "no change".
Time to global health status/quality of life deterioration per EORTC QLQ-C30 Up to 5 years PRO for adults as measured by the Functional Assessment of Cancer Therapy (FACT) - melanoma Up to 5 Years The FACT-M is a melanoma-specific quality of life questionnaire that is composed of items from the Functional Assessment of Cancer Therapy-General (FACT-G). The FACT-M is scored on a 5 point Likert-scale: "Not at all", "A little bit", "Somewhat", "Quite a bit", and "Very much.". A Higher score represents higher Health Related Quality of Life (HRQoL).
Time to role functioning deterioration per EORTC QLQ-C30 Up to 5 Years
Trial Locations
- Locations (211)
UC San Diego
🇺🇸La Jolla, California, United States
UCSF Medical Center at Mission Bay
🇺🇸San Francisco, California, United States
John Wayne Cancer Institute (JWCI)
🇺🇸Santa Monica, California, United States
The Melanoma And Skin Cancer Institute
🇺🇸Englewood, Colorado, United States
Miami Cancer Institute at Baptist Health, Inc.
🇺🇸Miami, Florida, United States
Orlando Health
🇺🇸Orlando, Florida, United States
Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Scroll for more (201 remaining)UC San Diego🇺🇸La Jolla, California, United States